# Michael A. Bookman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-a-bookman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,835 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 63 |
| i10-index | 155 |
| Last Known Institution | Kaiser Permanente |
| OpenAlex ID | https://openalex.org/A5058244284 |
| ORCID iD | https://orcid.org/0000-0002-4255-7814 |
| Works | 329 |

## Researcher papers

- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup](https://scholariq.org/papers/evaluation-of-new-platinum-based-treatment-regimens-in-advanced-stage-ovarian/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of/)
- [Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-2/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Kaiser Permanente](https://scholariq.org/institutions/kaiser-permanente/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.